Literature DB >> 28868240

JAK3-mediated phosphorylation of EZH2: a novel mechanism of non-canonical EZH2 activation and oncogenic function.

Theodoros Karantanos1,2,3, Vassiliki A Boussiotis1,2.   

Abstract

Entities:  

Year:  2016        PMID： 28868240      PMCID： PMC5578425          DOI： 10.21037/tcr.2016.11.11

Source DB:  PubMed          Journal:  Transl Cancer Res        ISSN： 2218-676X            Impact factor:   1.241


× No keyword cloud information.
  19 in total

1.  Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas.

Authors:  Sebastian Bender; Yujie Tang; Anders M Lindroth; Volker Hovestadt; David T W Jones; Marcel Kool; Marc Zapatka; Paul A Northcott; Dominik Sturm; Wei Wang; Bernhard Radlwimmer; Jonas W Højfeldt; Nathalène Truffaux; David Castel; Simone Schubert; Marina Ryzhova; Huriye Seker-Cin; Jan Gronych; Pascal David Johann; Sebastian Stark; Jochen Meyer; Till Milde; Martin Schuhmann; Martin Ebinger; Camelia-Maria Monoranu; Anitha Ponnuswami; Spenser Chen; Chris Jones; Olaf Witt; V Peter Collins; Andreas von Deimling; Nada Jabado; Stephanie Puget; Jacques Grill; Kristian Helin; Andrey Korshunov; Peter Lichter; Michelle Monje; Christoph Plass; Yoon-Jae Cho; Stefan M Pfister
Journal:  Cancer Cell       Date:  2013-10-31       Impact factor: 31.743

2.  Context-specific regulation of NF-κB target gene expression by EZH2 in breast cancers.

Authors:  Shuet Theng Lee; Zhimei Li; Zhenlong Wu; Meiyee Aau; Peiyong Guan; R K Murthy Karuturi; Yih Cherng Liou; Qiang Yu
Journal:  Mol Cell       Date:  2011-09-02       Impact factor: 17.970

3.  Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma.

Authors:  Peter W Lewis; Manuel M Müller; Matthew S Koletsky; Francisco Cordero; Shu Lin; Laura A Banaszynski; Benjamin A Garcia; Tom W Muir; Oren J Becher; C David Allis
Journal:  Science       Date:  2013-03-28       Impact factor: 47.728

Review 4.  Extranodal NK/T-cell lymphoma: diagnosis and treatment cues.

Authors:  Ritsuro Suzuki; Kengo Takeuchi; Koichi Ohshima; Shigeo Nakamura
Journal:  Hematol Oncol       Date:  2008-06       Impact factor: 5.271

5.  EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity.

Authors:  Junli Yan; Siok-Bian Ng; Jim Liang-Seah Tay; Baohong Lin; Tze Loong Koh; Joy Tan; Viknesvaran Selvarajan; Shaw-Cheng Liu; Chonglei Bi; Shi Wang; Shoa-Nian Choo; Norio Shimizu; Gaofeng Huang; Qiang Yu; Wee-Joo Chng
Journal:  Blood       Date:  2013-03-25       Impact factor: 22.113

6.  Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells.

Authors:  Eunhee Kim; Misuk Kim; Dong-Hun Woo; Yongjae Shin; Jihye Shin; Nakho Chang; Young Taek Oh; Hong Kim; Jingeun Rheey; Ichiro Nakano; Cheolju Lee; Kyeung Min Joo; Jeremy N Rich; Do-Hyun Nam; Jeongwu Lee
Journal:  Cancer Cell       Date:  2013-05-16       Impact factor: 31.743

7.  JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma.

Authors:  A Bouchekioua; L Scourzic; O de Wever; Y Zhang; P Cervera; A Aline-Fardin; T Mercher; P Gaulard; R Nyga; D Jeziorowska; L Douay; W Vainchenker; F Louache; C Gespach; E Solary; P Coppo
Journal:  Leukemia       Date:  2013-05-21       Impact factor: 11.528

8.  High-dose chemotherapy with autologous stem cell transplantation in extranodal NK/T-cell lymphoma: a retrospective comparison with non-transplantation cases.

Authors:  H J Kim; S M Bang; J Lee; H C Kwon; C Suh; H J Kim; J H Lee; B Y Ryoo; Y H Park; J M Kwon; S Y Oh; H R Lee; K Kim; C W Jung; K Park; W S Kim
Journal:  Bone Marrow Transplant       Date:  2006-05       Impact factor: 5.483

9.  Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers.

Authors:  Yongkun Wei; Weiya Xia; Zhihong Zhang; Jinsong Liu; Huamin Wang; Nazmi V Adsay; Constance Albarracin; Dihua Yu; James L Abbruzzese; Gordon B Mills; Robert C Bast; Gabriel N Hortobagyi; Mien-Chie Hung
Journal:  Mol Carcinog       Date:  2008-09       Impact factor: 4.784

10.  Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.

Authors:  Erick Riquelme; Carmen Behrens; Heather Y Lin; George Simon; Vassiliki Papadimitrakopoulou; Julie Izzo; Cesar Moran; Neda Kalhor; J Jack Lee; John D Minna; Ignacio I Wistuba
Journal:  Cancer Res       Date:  2015-12-16       Impact factor: 12.701
View more
  2 in total

1.  Antihistamine Drug Ebastine Inhibits Cancer Growth by Targeting Polycomb Group Protein EZH2.

Authors:  Qiaqia Li; Kilia Y Liu; Qipeng Liu; Guangyu Wang; Weihua Jiang; Qingshu Meng; Yang Yi; Yongyong Yang; Rui Wang; Sen Zhu; Chao Li; Longxiang Wu; Dongyu Zhao; Lin Yan; Lili Zhang; Jung-Sun Kim; Xiongbing Zu; Anthony J Kozielski; Wei Qian; Jenny C Chang; Akash Patnaik; Kaifu Chen; Qi Cao
Journal:  Mol Cancer Ther       Date:  2020-08-27       Impact factor: 6.261

2.  Inhibition of EZH2 induces NK cell-mediated differentiation and death in muscle-invasive bladder cancer.

Authors:  Swathi Ramakrishnan; Victoria Granger; Monika Rak; Qiang Hu; Kristopher Attwood; Lanni Aquila; Nithya Krishnan; Rafal Osiecki; Gissou Azabdaftari; Khurshid Guru; Gurkamal Chatta; Geraldine Gueron; Lacey McNally; Joyce Ohm; Jianmin Wang; Anna Woloszynska
Journal:  Cell Death Differ       Date:  2019-01-28       Impact factor: 15.828
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.